DALLAS, TEXAS, UNITED STATES. A new sunscreen ingredient called bemotrizinol is reaching American consumers after the U.S. Food and Drug Administration (FDA) added it to the permitted active ingredients for over-the-counter sunscreen products in 2026. The filter has been used in Europe and other international markets for decades.
The development comes as Texas is projected to record 5,910 new invasive melanoma cases and 480 melanoma deaths in 2026. Although bemotrizinol expands the options available to sunscreen manufacturers, consistent UV protection and awareness of suspicious skin changes remain essential.
A New Option for Sunscreen
Bemotrizinol, also known as BEMT, is an ultraviolet filter that protects against both UVA and UVB radiation. These forms of ultraviolet radiation can damage skin cells, contribute to premature skin ageing and increase the risk of skin cancer.
On June 9, 2026, the FDA announced the addition of bemotrizinol to its over-the-counter sunscreen monograph. The agency issued its final administrative order on June 10, and the order took effect on August 9, 2026.
This marks the first addition of a new active ingredient to the U.S. over-the-counter sunscreen monograph since the late 1990s, according to the FDA’s announcement on expanding sunscreen options.
The decision followed a request from DSM Nutritional Products LLC. The FDA reviewed information submitted by the company, relevant scientific literature and public comments before finalizing the order. The permitted concentration is up to 6%, subject to the conditions specified in the final order.
The FDA concluded that the available evidence supported the ingredient’s safety and effectiveness under these conditions. The agency also considered its low absorption through the skin.
The change allows qualifying sunscreen formulations containing bemotrizinol to enter the U.S. market under the applicable regulatory requirements. It does not mean that every product containing the ingredient automatically provides the same level of protection.
How Bemotrizinol Protects Skin
UVA and UVB Protection
UVA rays penetrate deeper into the skin and contribute to premature ageing and cellular damage. UVB rays are a major cause of sunburn. Both types of radiation can contribute to skin cancer.
Bemotrizinol absorbs ultraviolet radiation and helps reduce the amount that reaches the skin. Its broad-spectrum properties allow manufacturers to incorporate protection against UVA and UVB rays into a single sunscreen formulation.
The ingredient is also known for its photostability, meaning it can maintain its chemical stability when exposed to light. This property is useful in sunscreen formulation, although it does not mean that a finished product remains effective indefinitely.
Sweating, swimming, towel drying and incomplete application can reduce the protection provided by sunscreen. Users must continue to follow the product’s application and reapplication instructions.
What the Regulatory Change Means
Bemotrizinol is not a newly developed chemical. Its importance lies in its addition to the U.S. sunscreen regulatory framework after decades of use in international markets.
The FDA’s decision followed a regulatory process established under the Coronavirus Aid, Relief, and Economic Security (CARES) Act. The agency issued a proposed order in December 2025 before finalizing the change in June 2026.
The final order also provides an 18-month exclusivity period tied to DSM Nutritional Products LLC and its qualifying licensees, assignees or successors. The federal government has presented the change as part of its broader effort to encourage innovation in the sunscreen market.
For consumers, the main development is an expanded choice of permitted sunscreen ingredients. The effectiveness of an individual product still depends on its complete formulation, labelled sun protection factor (SPF), water resistance and correct use.
Sunscreens Begin Reaching Stores
The regulatory change has started translating into products for American consumers.
Neutrogena lists two facial sunscreens containing bemotrizinol: Ultra Sheer Daily Face Sunscreen SPF 70 and Clear Face Sunscreen SPF 60. The brand’s current facial sunscreen range identifies both products as containing BEMT.
Australian skincare brand Ultra Violette has also introduced products containing bemotrizinol to the U.S. market. La Roche-Posay has announced a sunscreen featuring the filter, although its U.S. BEMT product page describes the launch as forthcoming.
Product availability can change by retailer and launch date. Consumers should check the current product label to confirm whether a sunscreen contains bemotrizinol rather than relying on the brand name alone.
The new ingredient does not make existing sunscreens obsolete. Products containing other permitted UV filters can continue to offer effective protection when they meet applicable standards and are used correctly.
Texas Melanoma Projections
The arrival of bemotrizinol comes amid continuing concern about melanoma, an aggressive form of skin cancer that develops from melanocytes, the cells responsible for producing skin pigment.
According to the American Cancer Society’s 2026 estimates, Texas is projected to record 5,910 new invasive melanoma cases and 480 melanoma deaths during the year. These figures are projections rather than confirmed final counts.
Nationally, approximately 112,000 invasive melanoma cases and 8,510 deaths are projected for 2026. The estimates also include 122,680 cases of melanoma in situ.
Melanoma in situ refers to cancerous melanocytes that remain confined to the epidermis, the outer layer of the skin. Invasive melanoma has grown beyond that layer. These categories describe different stages of disease and should not be treated as interchangeable.
The American Cancer Society’s melanoma statistics explain that melanoma accounts for about 1% of skin cancers but causes a large majority of skin cancer deaths.
A report by The Dallas Express published on October 17, 2026, highlighted the new sunscreen ingredient alongside Texas’s projected melanoma burden and the continuing need for sun protection.
Melanoma risk is influenced by several factors, including ultraviolet exposure, a history of sunburn, certain mole patterns, family history and individual susceptibility. People of every skin tone can develop melanoma, although risk differs among individuals.
The projected figures emphasize the importance of prevention and early recognition. They should not, by themselves, be interpreted as a measure of how much melanoma incidence has increased in Texas.
Skin Cancer Beyond Melanoma
Melanoma is not the only skin cancer associated with UV exposure. Basal cell carcinoma and squamous cell carcinoma are much more common, although they generally behave differently from melanoma.
More than five million basal cell and squamous cell skin cancers are estimated to be diagnosed in the United States each year. The actual number is difficult to establish because these cancers are not routinely reported to central cancer registries.
The CDC separately estimates that approximately 6.1 million adults receive treatment for basal cell and squamous cell carcinomas annually, at a cost of around $8.9 billion.
These figures describe different measures of skin cancer burden and should not be added together. They nevertheless demonstrate the wider health and healthcare impact of skin cancer.
Most skin cancers are associated with excessive exposure to ultraviolet radiation from sunlight or artificial tanning devices. Reducing avoidable UV exposure is therefore an important part of prevention.
Sun Protection During Cooler Weather
Cool temperatures do not necessarily mean low UV exposure. Ultraviolet radiation can reach the skin on cloudy days and during autumn and winter.
The FDA reports that as much as 80% of the sun’s UV radiation can pass through cloud cover. Actual exposure depends on factors such as location, altitude, season, time of day and reflection from surrounding surfaces.
The CDC’s sun safety guidance recommends protection throughout the year, particularly when the UV Index reaches 3 or higher.
People can reduce exposure by seeking shade, wearing clothing that covers exposed skin, using a broad-brimmed hat and choosing sunglasses that block UVA and UVB rays. Avoiding tanning beds is also important.
Sunscreen remains one part of this approach. The American Cancer Society recommends broad-spectrum sunscreen with SPF 30 or higher as part of a broader sun protection routine.
Choosing and Applying Sunscreen
Consumers should choose broad-spectrum sunscreen that protects against both UVA and UVB radiation. A product with SPF 30 or higher is a practical choice for routine sun protection.
SPF measures protection against sunburn under specified testing conditions. It does not indicate how many hours someone can remain in the sun without skin damage, and it does not mean that all UV radiation is blocked.
Apply sunscreen generously and evenly to exposed skin before going outdoors, following the product label. Pay attention to commonly missed areas such as the ears, back of the neck, hairline, hands, lips and tops of the feet.
Reapply at least every two hours while outdoors and more often when swimming or sweating. Water-resistant products are labelled for either 40 or 80 minutes of water exposure, so users should follow the directions for their specific product.
The FDA’s sunscreen application guidance also recommends combining sunscreen with protective clothing and shade. No sunscreen blocks all UV radiation, and no single ingredient eliminates skin cancer risk.
Recognizing Possible Melanoma
Sun protection does not remove the need to pay attention to changes in the skin. Melanoma can develop in an existing mole or appear as a new spot.
The ABCDE method can help identify changes that require medical assessment:
- Asymmetry: One half of the spot looks different from the other.
- Border: The edges are irregular or uneven.
- Color: The spot has inconsistent color or several shades.
- Diameter: The spot is often larger than 6 millimeters, although melanoma can be smaller.
- Evolving: The spot changes in size, shape, color or appearance.
Other warning signs include a sore that does not heal, persistent itching, bleeding or a mark that looks different from surrounding moles.
These features cannot confirm a diagnosis on their own. A new or changing spot should be assessed by a qualified healthcare professional, particularly if it continues to evolve.
The American Cancer Society’s guidance on melanoma symptoms explains that a new or changing skin spot is an important warning sign. Prompt assessment can help identify melanoma before it progresses.
Conclusion
Bemotrizinol’s arrival in the United States marks an important change in sunscreen regulation after decades without a new active ingredient being added to the over-the-counter sunscreen monograph. Its broad-spectrum UV protection gives manufacturers another option when developing sunscreen formulations.
At the same time, Texas’s projected 5,910 invasive melanoma cases in 2026 underline the continuing importance of skin cancer prevention and early recognition. The new filter does not replace established sun safety measures or remove the need to monitor suspicious skin changes.
Choosing broad-spectrum sunscreen, applying it correctly, seeking shade, wearing protective clothing and avoiding tanning beds remain essential measures for reducing UV exposure.
Consistent habits, combined with prompt medical evaluation of concerning skin changes, offer a more complete approach to skin health.
